Price range: $50.99 through $96.99
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin, studied for innate repair receptor signaling without erythropoietic activity in preclinical models.
ARA-290, also known as cibinetide, is an 11-amino-acid linear peptide derived from the helix B region of erythropoietin (EPO). The literature sometimes refers to it as pyroglutamate helix B surface peptide (pHBSP). It was designed to retain certain tissue-protective signaling properties of EPO while lacking its effects on red blood cell production. Its sequence begins with pyroglutamic acid, a cyclized residue that blocks the N-terminus.
Erythropoietin acts on two receptor types. The classical EPO receptor homodimer drives erythropoiesis, while a heteromeric complex of the EPO receptor and the beta common receptor (CD131), termed the innate repair receptor, has been linked to tissue-protective and anti-inflammatory signaling. ARA-290 was engineered to engage this second receptor selectively. In animal studies it did not raise hematocrit, which made it useful for isolating the non-hematopoietic side of EPO biology.
Preclinical research has examined ARA-290 in models of neuropathic pain, peripheral nerve injury, diabetes, and ischemia-reperfusion injury, with measurements of inflammatory cytokines and small nerve fiber density. Clinical investigations in sarcoidosis-associated small fiber neuropathy have added to its published record.
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. Sold to qualified researchers for in-vitro and laboratory research.
| Weight | 16mg, 8mg |
|---|
